In patients with CTP class A HCC, we compared the rate of adverse events among those reclassified as IGF/CTP-A (AA) to that of patients reclassified as IGF/CTP-B (AB) (Supplementary Table 4). The gene discussed is IGF1; the disease is hepatocellular carcinoma.